title: Preoperative erythropoietin alpha reduces postoperative transfusions in THA and TKA but may not be cost-effective.
abstract: BACKGROUND
  Preoperative erythropoietin alpha (EPO) has been shown to be effective at reducing postoperative blood transfusions in total hip arthroplasty (THA) and total knee arthroplasty (TKA); however, treatment with EPO is associated with additional costs, and it is not known whether these costs can be justified when weighed against the transfusion reductions achieved in patients who receive the drug.
  
  
  OBJECTIVE
  The purpose of this study is to investigate (1) efficacy of preoperative EPO in reducing postoperative transfusions in TKA and THA; (2) whether patients treated with EPO have reduced length of stay or a different discharge disposition; and (3) whether EPO use reduces overall blood management costs.
  
  
  METHODS
  Patients undergoing primary THA or TKA over a 10-month period with preoperative hemoglobin<13 g/dL were recommended to be treated preoperatively with EPO. During that time, 80 of 286 (28%) patients met that inclusion criterion and the treating team recommended EPO to all of them; of that group, 24 (30%) opted to take EPO and 56 (70%) opted not to. Patients receiving at least one dose of EPO and those not receiving EPO were compared in terms of transfusion frequency, length of stay and discharge disposition, and overall blood management costs. Demographics, preoperative hemoglobin, and operative blood loss for both groups were similar (p>0.05). No transfusion triggers were used; rather, patients with postoperative hemoglobin<10 mg/dL and who were symptomatic despite fluid boluses were transfused. The clinician responsible for transfusing symptomatic patients was blinded to the patient's EPO treatment status. Costs were defined as direct costs paid or incurred by our institution for EPO, allogeneic blood, and variable costs associated with patient care after THA/TKA. A decision-tree cost analysis was performed using the collected clinical data and cost data collected from our institution; the analysis considered total associated blood management cost for an EPO and a non-EPO strategy with sensitivity analysis of key cost variables.
  
  
  RESULTS
  The proportion of patients receiving transfusions was lower in patients who received EPO than in patients who did not (0% [zero of 24] versus 41% [23 of 56]; p<0.001). The mean length of inpatient hospital stay (EPO: 3.0±0.4 versus control: 3.3±0.8 days, p=0.77) and discharge disposition also was not different between the groups. The cost analysis demonstrated that the EPO strategy was more costly compared with no EPO (USD 2632 versus USD 2284) and its cost would need to be less than USD 225/dose for this to change.
  
  
  CONCLUSIONS
  EPO reduced the need for postoperative transfusions in high-risk patients undergoing THA and TKA; however, it was not found to be cost-effective in our model. Our model could not consider relatively rare complications of blood transfusions, including disease transmission, deep periprosthetic infections, and transfusion reactions, but if surgeons or patients value avoiding these potential but rare factors highly, this could reasonably influence the decision of whether to use EPO despite our findings that it was not cost-effective.
  
  
  METHODS
  Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
authors.affiliation: Department of Orthopaedics, Massachusetts General Hospital, Boston, MA, USA, hbedair@partners.org.
authors.forename: Hany
authors.initials: H
authors.lastname: Bedair
authors.forename: Judy
authors.initials: J
authors.lastname: Yang
authors.forename: Maureen K
authors.initials: MK
authors.lastname: Dwyer
authors.forename: Joseph C
authors.initials: JC
authors.lastname: McCarthy
mesh_terms: D000368:Aged; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D001803:Blood Transfusion / Q000191:economics* / Q000706:statistics & numerical data*; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004921:Erythropoietin / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period
chemical_list: D004921:Erythropoietin
references.citation: Transfusion. 2007 Mar;47(3):379-84
references.pmid: 17319816
references.citation: Br J Anaesth. 2012 Jun;108(6):943-52
references.pmid: 22593128
references.citation: J Bone Joint Surg Br. 2012 Nov;94(11 Suppl A):8-10
references.pmid: 23118371
references.citation: Br J Anaesth. 2007 Dec;99(6):794-800
references.pmid: 17928302
references.citation: J Arthroplasty. 2013 Sep;28(8 Suppl):137-9
references.pmid: 23886409
references.citation: J Bone Joint Surg Am. 2000 Jan;82(1):89-100
references.pmid: 10653088
references.citation: Acta Orthop. 2005 Jun;76(3):314-9
references.pmid: 16156456
references.citation: Clin Orthop Relat Res. 2010 Jul;468(7):1905-11
references.pmid: 20063079
references.citation: Anesthesiology. 2006 Jul;105(1):198-208
references.pmid: 16810012
references.citation: Acta Orthop. 2008 Apr;79(2):168-73
references.pmid: 18484241
references.citation: Anesth Analg. 2004 Jul;99(1):262-271
references.pmid: 15281542
references.citation: Am J Surg. 2004 Feb;187(2):261-7
references.pmid: 14769316
references.citation: J Bone Joint Surg Br. 2007 Aug;89(8):1092-7
references.pmid: 17785752
references.citation: Br J Anaesth. 1997 Sep;79(3):317-21
references.pmid: 9389848
references.citation: Vox Sang. 1999;77(1):11-6
references.pmid: 10474085
references.citation: Can J Anaesth. 2005 Feb;52(2):160-5
references.pmid: 15684256
references.citation: Acta Orthop Scand. 1998 Feb;69(1):31-4
references.pmid: 9524514
references.citation: J Bone Joint Surg Br. 2009 Jun;91(6):776-83
references.pmid: 19483232
references.citation: Transfus Med. 1999 Mar;9(1):21-30
references.pmid: 10216902
references.citation: J Bone Joint Surg Am. 2004 Jul;86(7):1512-8
references.pmid: 15252101
references.citation: J Orthop Surg Res. 2011 May 21;6:22
references.pmid: 21600028
references.citation: J Bone Joint Surg Am. 1999 Jan;81(1):2-10
references.pmid: 9973048
references.citation: J Bone Joint Surg Am. 2012 Jul 3;94(13):1153-9
references.pmid: 22623147
references.citation: J Bone Joint Surg Br. 2003 May;85(4):484-9
references.pmid: 12793549
references.citation: J Arthroplasty. 2010 Jan;25(1):93-6
references.pmid: 19056224
references.citation: J Arthroplasty. 2005 Jun;20(4 Suppl 2):51-4
references.pmid: 15991130
references.citation: J Bone Joint Surg Am. 2003 Sep;85(9):1795-800
references.pmid: 12954840
references.citation: JAMA. 2010 Oct 13;304(14):1559-67
references.pmid: 20940381
references.citation: J Arthroplasty. 2006 Aug;21(5):628-35
references.pmid: 16877146
references.citation: Orthopedics. 1999 Jan;22(1 Suppl):s105-12
references.pmid: 9927110
references.citation: N Engl J Med. 2011 Dec 29;365(26):2453-62
references.pmid: 22168590
references.citation: Acta Orthop Belg. 2004 Oct;70(5):466-73
references.pmid: 15587036
references.citation: Clin Orthop Relat Res. 2004 Jun;(423):240-4
references.pmid: 15232456
references.citation: Clin Orthop Relat Res. 2014 Jan;472(1):66-72
references.pmid: 23817754
references.citation: Eur J Anaesthesiol. 2005 Apr;22(4):249-57
references.pmid: 15892401
references.citation: N Engl J Med. 1995 Mar 16;332(11):719-24
references.pmid: 7854380
references.citation: Blood Coagul Fibrinolysis. 2012 Jun;23(4):278-84
references.pmid: 22343689
references.citation: Vox Sang. 2010 Jan;98(1):56-64
references.pmid: 19656349